Monday, July 17, 1995
Path clear for acellular pertussis vaccines
Positive results in two large trials of several acellular pertussis vaccines have
validated the technology, and is likely to result in rapid approval of the new vaccines to
replace the currently marketed whole killed vaccines.
The National Institute of Allergy and Infectious Diseases (NIAID) announced results of
Phase III trials of acellular pertussis vaccines in Italy and Sweden, showing increased
efficacy in protecting infants and decreased side effects, compared to both whole-cell DTP
(diphtheria-tetanus-pertussis) vaccines and DT vaccines. The institute emphasized that it
will work closely with the FDA to speed approvals for the vaccines.